A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patients

R M Naimi; K B Madsen; C Askov-Hansen; C F Brandt; B Hartmann; Jens Juul Holst; P B Mortensen; P B Jeppesen

doi:10.1016/j.regpep.2013.03.023

A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patients

R M Naimi, K B Madsen, C Askov-Hansen, C F Brandt, B Hartmann, Jens Juul Holst, P B Mortensen, P B Jeppesen

Research output: Contribution to journal › Journal article › Research › peer-review

8 Citations (Scopus)

Abstract

Glucagon-like peptide 2 (GLP-2), secreted endogenously from L-cells in the distal bowel in relation to meals, modulates intestinal absorption by adjusting gastric emptying and secretion and intestinal growth. Short bowel syndrome (SBS) patients with distal intestinal resections have attenuated endogenous GLP-2 secretion, which may contribute to their rapid gastric emptying, gastric hypersecretion and poor intestinal adaptation, whereas SBS patients with preserved terminal ileum and colon, who have a constantly elevated GLP-2 secretion, seem to do better in these respects. This study compared effects of continuous, subcutaneous (s.c.), exogenous GLP-2 infusion (CONT-GLP-2) versus three daily s.c. GLP-2 injections (TID-GLP-2) on intestinal absorption in SBS patients.

Original language	English
Journal	Regulatory Peptides
Volume	184
Issue number	10
Pages (from-to)	47-53
Number of pages	7
ISSN	0167-0115
DOIs	https://doi.org/10.1016/j.regpep.2013.03.023
Publication status	Published - 10 Jun 2013

Access to Document

10.1016/j.regpep.2013.03.023

Cite this

Naimi, R. M., Madsen, K. B., Askov-Hansen, C., Brandt, C. F., Hartmann, B., Holst, J. J., Mortensen, P. B., & Jeppesen, P. B. (2013). A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patients. Regulatory Peptides, 184(10), 47-53. https://doi.org/10.1016/j.regpep.2013.03.023

A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patients. / Naimi, R M; Madsen, K B; Askov-Hansen, C; Brandt, C F; Hartmann, B ; Holst, Jens Juul; Mortensen, P B; Jeppesen, P B.

In: Regulatory Peptides, Vol. 184, No. 10, 10.06.2013, p. 47-53.

Research output: Contribution to journal › Journal article › Research › peer-review

Naimi, RM, Madsen, KB, Askov-Hansen, C, Brandt, CF, Hartmann, B , Holst, JJ, Mortensen, PB & Jeppesen, PB 2013, 'A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patients', Regulatory Peptides, vol. 184, no. 10, pp. 47-53. https://doi.org/10.1016/j.regpep.2013.03.023

Naimi RM, Madsen KB, Askov-Hansen C, Brandt CF, Hartmann B , Holst JJ et al. A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patients. Regulatory Peptides. 2013 Jun 10;184(10):47-53. https://doi.org/10.1016/j.regpep.2013.03.023

Naimi, R M ; Madsen, K B ; Askov-Hansen, C ; Brandt, C F ; Hartmann, B ; Holst, Jens Juul ; Mortensen, P B ; Jeppesen, P B. / A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patients. In: Regulatory Peptides. 2013 ; Vol. 184, No. 10. pp. 47-53.

@article{7264c92fe3544ac4bc7b801eee696b2e,

title = "A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patients",

abstract = "Glucagon-like peptide 2 (GLP-2), secreted endogenously from L-cells in the distal bowel in relation to meals, modulates intestinal absorption by adjusting gastric emptying and secretion and intestinal growth. Short bowel syndrome (SBS) patients with distal intestinal resections have attenuated endogenous GLP-2 secretion, which may contribute to their rapid gastric emptying, gastric hypersecretion and poor intestinal adaptation, whereas SBS patients with preserved terminal ileum and colon, who have a constantly elevated GLP-2 secretion, seem to do better in these respects. This study compared effects of continuous, subcutaneous (s.c.), exogenous GLP-2 infusion (CONT-GLP-2) versus three daily s.c. GLP-2 injections (TID-GLP-2) on intestinal absorption in SBS patients.",

author = "Naimi, {R M} and Madsen, {K B} and C Askov-Hansen and Brandt, {C F} and B Hartmann and Holst, {Jens Juul} and Mortensen, {P B} and Jeppesen, {P B}",

year = "2013",

month = jun,

day = "10",

doi = "10.1016/j.regpep.2013.03.023",

language = "English",

volume = "184",

pages = "47--53",

journal = "Regulatory Peptides",

issn = "0167-0115",

publisher = "Elsevier",

number = "10",

}

TY - JOUR

T1 - A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patients

AU - Naimi, R M

AU - Madsen, K B

AU - Askov-Hansen, C

AU - Brandt, C F

AU - Hartmann, B

AU - Holst, Jens Juul

AU - Mortensen, P B

AU - Jeppesen, P B

PY - 2013/6/10

Y1 - 2013/6/10

N2 - Glucagon-like peptide 2 (GLP-2), secreted endogenously from L-cells in the distal bowel in relation to meals, modulates intestinal absorption by adjusting gastric emptying and secretion and intestinal growth. Short bowel syndrome (SBS) patients with distal intestinal resections have attenuated endogenous GLP-2 secretion, which may contribute to their rapid gastric emptying, gastric hypersecretion and poor intestinal adaptation, whereas SBS patients with preserved terminal ileum and colon, who have a constantly elevated GLP-2 secretion, seem to do better in these respects. This study compared effects of continuous, subcutaneous (s.c.), exogenous GLP-2 infusion (CONT-GLP-2) versus three daily s.c. GLP-2 injections (TID-GLP-2) on intestinal absorption in SBS patients.

AB - Glucagon-like peptide 2 (GLP-2), secreted endogenously from L-cells in the distal bowel in relation to meals, modulates intestinal absorption by adjusting gastric emptying and secretion and intestinal growth. Short bowel syndrome (SBS) patients with distal intestinal resections have attenuated endogenous GLP-2 secretion, which may contribute to their rapid gastric emptying, gastric hypersecretion and poor intestinal adaptation, whereas SBS patients with preserved terminal ileum and colon, who have a constantly elevated GLP-2 secretion, seem to do better in these respects. This study compared effects of continuous, subcutaneous (s.c.), exogenous GLP-2 infusion (CONT-GLP-2) versus three daily s.c. GLP-2 injections (TID-GLP-2) on intestinal absorption in SBS patients.

U2 - 10.1016/j.regpep.2013.03.023

DO - 10.1016/j.regpep.2013.03.023

M3 - Journal article

C2 - 23501043

VL - 184

SP - 47

EP - 53

JO - Regulatory Peptides

JF - Regulatory Peptides

SN - 0167-0115

IS - 10

ER -